ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Healthcare costs associated with gender dysphoria in children, adolescents and young adults in germany: A prevalence-based analysis using statutory health insurance data.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the past decade, there has been an increase in individuals presenting to healthcare services with gender dysphoria (GD), the psychological distress that may arise when an individual's birth-assigned sex does not align with his/her experienced gender. The current study aimed to analyze resource use and costs associated with prevalent GD in individuals aged 4 to 30 years.
methodsThe analysis was a prevalence-based cost study using data of the two largest German health insurance funds (BARMER and TK) from 2018, 2019, and 2020. Individuals with prevalent GD were identified based on ICD-10 diagnosis codes related to gender dysphoria. These were compared to a control group balanced for (1) age, birth-assigned sex, degree of urbanization, and (2) additionally for psychiatric diagnoses using entropy balancing. Outcomes of interest were total and sector-specific annual costs (outpatient, inpatient, medications) and health-related resource use (hospital days, defined daily doses of medications). Groups were compared stratified by age groups, birth-assigned sex, and for a subgroup of individuals with GD receiving hormonal therapy.
resultsIndividuals with prevalent GD aged 4-30 years had higher average resource use and costs compared to controls, with little variation between years (e.g. difference in 2019 +€4,843 [95% confidence interval €4,306; €5,380], balanced for age, birth-assigned sex, degree of urbanization). The group difference was observed across age groups and healthcare sectors, with the largest differences found in somatic and psychiatric inpatient hospitalizations, and with psychiatric costs accounting for 50% of the total cost difference. Comparing individuals with GD receiving hormonal therapy with controls, the difference in total costs was similar, but the contribution of psychiatric costs was less pronounced (29%). The cost difference decreased considerably in all subgroups and sectors when psychiatric diagnoses were additionally balanced for.
conclusionsIndividuals with GD aged 4-30 years had higher annual resource use and costs than controls. Future studies analyzing resource use and costs over multiple years and examining the temporal association between GD and psychiatric disorders would allow a more accurate estimate of the costs directly attributable to GD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.